These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 20085865

  • 1. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
    Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN.
    Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A.
    J Clin Oncol; 2006 Mar 20; 24(9):1443-8. PubMed ID: 16549838
    [Abstract] [Full Text] [Related]

  • 3. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
    Li L, Razak AR, Hughes A.
    Lung Cancer; 2009 May 20; 64(2):207-10. PubMed ID: 18926592
    [Abstract] [Full Text] [Related]

  • 4. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.
    J Thorac Oncol; 2008 Jul 20; 3(7):756-63. PubMed ID: 18594322
    [Abstract] [Full Text] [Related]

  • 5. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M.
    Lung Cancer; 2012 Mar 20; 75(3):360-7. PubMed ID: 21937142
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M.
    Jpn J Clin Oncol; 2008 May 20; 38(5):339-46. PubMed ID: 18434338
    [Abstract] [Full Text] [Related]

  • 7. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
    Kuribayashi K, Voss S, Nishiuma S, Arakawa K, Nogi Y, Mikami K, Kudoh S.
    Lung Cancer; 2012 Mar 20; 75(3):353-9. PubMed ID: 21890228
    [Abstract] [Full Text] [Related]

  • 8. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
    Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA, Pemetrexed Expanded Access Program Investigators.
    Lung Cancer; 2007 Feb 20; 55(2):187-94. PubMed ID: 17092602
    [Abstract] [Full Text] [Related]

  • 9. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.
    In Vivo; 2006 Feb 20; 20(6A):715-8. PubMed ID: 17203752
    [Abstract] [Full Text] [Related]

  • 10. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
    Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, Griffin M, Fishwick K, Boddy AV, Verrill M, Calvert H.
    J Clin Oncol; 2002 Aug 15; 20(16):3533-44. PubMed ID: 12177114
    [Abstract] [Full Text] [Related]

  • 11. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY, Zhang H, Bai H, Wang SH, Wu MN, An TT, Zhao J, Zhuo ML, Duan JC, Wang ZJ, Wang J.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar 15; 36(3):162-8. PubMed ID: 23856136
    [Abstract] [Full Text] [Related]

  • 12. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
    Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A.
    Lung Cancer; 2011 Apr 15; 72(1):73-7. PubMed ID: 21216487
    [Abstract] [Full Text] [Related]

  • 13. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.
    J Thorac Oncol; 2008 Jul 15; 3(7):764-71. PubMed ID: 18594323
    [Abstract] [Full Text] [Related]

  • 14. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
    Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A.
    Clin Cancer Res; 2011 Apr 15; 17(8):2581-90. PubMed ID: 21262916
    [Abstract] [Full Text] [Related]

  • 15. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
    Reck M, Stahel RA, von Pawel J, Karthaus M, Korfee S, Serke M, Schuette WH, Eschbach C, Fink TH, Leschinger MI, Manegold C.
    Respir Med; 2010 Jan 15; 104(1):142-8. PubMed ID: 19818589
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.
    J Clin Oncol; 2009 Apr 20; 27(12):2038-45. PubMed ID: 19307503
    [Abstract] [Full Text] [Related]

  • 17. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM).
    Pasello G, Marulli G, Polo V, Breda C, Bonanno L, Loreggian L, Rea F, Favaretto A.
    Anticancer Res; 2012 Dec 20; 32(12):5393-9. PubMed ID: 23225442
    [Abstract] [Full Text] [Related]

  • 18. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA.
    Eur J Radiol; 2012 Jan 20; 81(1):e19-25. PubMed ID: 21129871
    [Abstract] [Full Text] [Related]

  • 19. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
    Razak AR, Chatten KJ, Hughes AN.
    Lung Cancer; 2008 May 20; 60(2):294-7. PubMed ID: 17919769
    [Abstract] [Full Text] [Related]

  • 20. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
    Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C.
    J Clin Oncol; 2008 Apr 01; 26(10):1698-704. PubMed ID: 18375898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.